NCT06444802View on ClinicalTrials.gov

Model-informed Precision Dosing for Linezolid

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

February 28, 2026

Study Completion Date

June 30, 2026

Conditions
Gram-Positive Bacterial Infections
Interventions
DRUG

Linezolid

Linezolid dosing will be adapted according to a model informed precision dosing (TDMx)

All Listed Sponsors
lead

University of Hamburg-Eppendorf

OTHER

NCT06444802 - Model-informed Precision Dosing for Linezolid | Biotech Hunter | Biotech Hunter